Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 31Dermatologic 13Plasma cell 5Other hematologic neoplasm 5Breast 3Gastrointestinal 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Pleural Effusion, Malignant 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × romidepsin × Thoracic × Clear all
NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

University of Texas Southwestern Medical Center

Phase 1 Completed
17 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡